All Releases
 |
Hana Biosciences Patent Issued for Menadione for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash
Jul 8, 2010
|
10.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jul 8, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it was issued U.S. patent number 7,745,494, which covers a method of using menadione topical lotion in treating skin rash in...
|
|
Hana Biosciences Announces Financing of Up to $100 Million
Jun 7, 2010
|
12.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 7, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management for the sale of up to $100 million ...
|
|
Data From Pivotal Phase 2 RALLY Trial Show Marqibo Produced Compelling Single-Agent Anti-Leukemic Efficacy in Advanced Relapsed/Refractory Adult Ph(-) Acute Lymphoblastic Leukemia
Jun 7, 2010
|
13.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 7, 2010 (GlobeNewswire via COMTEX News Network) --
-- Marqibo administered as third-, fourth-, fifth-, and sixth-line
single-agent therapy
-- 35% overall response rate with a predictable and manageable toxicity
profile
-- 20% complete response (CR) and CR with incomplete blood count recove...
|
|
Hana Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference
Jun 3, 2010
|
7.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 3, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences, Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced its participation in the Jefferies 2010 Global Life Sciences Conference to be held June 8 through June 11, 2010 in New York City ...
|
|
Hana Biosciences Reports First Quarter 2010 Financial Results
May 14, 2010
|
16.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 14, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
"During the first quarter of 2...
|
|
Hana Biosciences Completes Pre-NDA Meeting With FDA for Marqibo in Adult Acute Lymphoblastic Leukemia
Apr 27, 2010
|
10.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 27, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the Company has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to it...
|
|
Hana Biosciences to Present Complete Data From Pivotal Phase 2 Trial of Marqibo in Acute Lymphoblastic Leukemia at American Society of Clinical Oncology 2010 Annual Meeting
Apr 22, 2010
|
10.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 22, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo(R) in patients with relapsed/refractory adult Philadelphia chromosome-negative ac...
|
|
Hana Biosciences Receives Notice of Allowance for Menadione Patent for the Prevention and Treatment of EGFR Inhibitor Cancer Therapy-Associated Rash
Mar 30, 2010
|
11.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 30, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for the use of menadione to prevent and t...
|
|
Hana Biosciences Reports Fourth Quarter and Year End 2009 Financial Results
Mar 25, 2010
|
16.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 25, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences Inc., (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the fourth quarter and year ended December 31, 2009, and provided a corporate update.
"In 2009, we made...
|
|
Hana Biosciences Appoints Craig W. Carlson as Chief Financial Officer
Mar 11, 2010
|
10.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 11, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that Craig W. Carlson has joined its Executive Committee and will assume the title of Chief Financial Officer, effective April 1, 2010...
|
|
Hana Biosciences to Present at the 12th Annual BIO CEO & Investor Conference
Feb 1, 2010
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 1, 2010 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the executive management team will participate in the 12th Annual BIO CEO & Investor Conference to be held February 8 through Febr...
|
|
Hana Biosciences Appoints Howard Furst, M.D., M.B.A., to Board of Directors
Dec 16, 2009
|
10.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 16, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the appointment of Howard Furst, M.D., M.B.A., to the Company's Board of Directors. Dr. Furst has over 20 years of experience in the h...
|
|
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Dec 7, 2009
|
12.5 KB |
|
| |
Dec 7, 2009 (GlobeNewswire via COMTEX News Network) --
--36% Overall Response Rate and 21% Complete Remission Rate--
--Median Overall Survival of 7.3 Months in Complete Responders--
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengtheni...
|
|
Hana Biosciences Completes Enrollment in Pivotal Phase 2 rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia
Dec 2, 2009
|
11.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 2, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has completed enrollment of its pivotal Phase 2 rALLy clinical trial for Marqibo(R) (vincristine sulfate liposomes injection) f...
|
|
Hana Biosciences to Present Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia
Dec 1, 2009
|
9.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 1, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that top-line data from its pivotal Phase 2 rALLy clinical trial for Marqibo(R) (vincristine sulfate liposomes injection) for the treat...
|
|
Hana Biosciences to Present at the 21st Annual Piper Jaffray Healthcare Conference
Nov 24, 2009
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 24, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that Steven R. Deitcher, M.D., President and Chief Executive Officer, will present an overview of the Company at the 21st Annual Piper...
|
|
Hana Biosciences Announces Third Quarter 2009 Results
Nov 13, 2009
|
16.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 13, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB) announced today financial results for the three and nine months ended September 30, 2009.
"Highlights of the past couple months include completion of a financing with top tier biotechnology investors and intensive preparation for o...
|
|
Hana Biosciences to Present at the 8th Annual BIO Investor Forum
Oct 22, 2009
|
7.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 22, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the executive management team will participate in the 8th Annual BIO Investor Forum to be held October 28 through October 29, 200...
|
|
Hana Biosciences Completes $12.4 Million Private Placement
Oct 8, 2009
|
9.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 8, 2009 (GlobeNewswire via COMTEX News Network) -- Hana Biosciences (OTCBB:HNAB) announced today that it has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million.
N...
|
|
Hana Biosciences Announces $12.4 Million Private Placement
Oct 8, 2009
|
11.6 KB |
|
| |
Oct 8, 2009 (GlobeNewswire via COMTEX News Network) --
* Financing led by OrbiMed Advisors LLC, Perceptive Life Sciences
Master Fund Ltd., Quogue Capital LLC and Deerfield Management
* Proceeds to be used to advance Hana's lead clinical compound
Marqibo(R)
SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- Hana Bios...
|
|
|
